Radiation Therapy News and Research

RSS

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.

New version of RaySearch's RayStation treatment planning system released for clinical use

RaySearch Laboratories AB announces that version 4.0 of RaySearch's RayStation treatment planning system has been released for clinical use in several European countries, USA, Japan, Australia and New Zealand, and is scheduled for market release in Canada, China, and South Korea.

23 Jul 2013

Elekta gets CE Mark approval for Clarity 4D Monitoring system

Elekta has received CE marking for its Clarity 4D Monitoring system permitting European clinics to implement this new way of reducing the uncertainty caused by prostate motion during radiation treatment. Physicians will be able to monitor the motion of the prostate with sub millimeter accuracy during the delivery of therapeutic radiation beams.

From Elekta 19 Jul 2013

Researchers patent biomaterial that generates artificial bones from umbilical cord stem cells

Scientists in Granada, Spain, have patented a new biomaterial that facilitates generating bone tissue-artificial bones in other words-from umbilical cord stem cells . The material, consisting of an activated carbon cloth support for cells that differentiate giving rise to a product that can promote bone growth, has recently been presented at a press conference at the Biomedical Research Centre, Granada.

19 Jul 2013

Phase 2 EORTC trial shows moderate dose radiotherapy is effective in desmoid-type fibromatosis patients

A phase 2 EORTC trial for patients with inoperable desmoid-type fibromatosis has shown that moderate dose radiotherapy is an effective treatment for patients with such a rare type of tumor. The study results published in Annals of Oncology show that response after radiation therapy is slow, and that continuing regression is seen even after three years.

19 Jul 2013

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

An experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier and kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

19 Jul 2013

Study brings new hope for patients with metastatic prostate cancer

A study of a new radiotherapeutic drug published this week in the New England Journal of Medicine brings fresh hope for a particular group of cancer patients that otherwise suffer and ultimately die from the disease -- those with prostate cancer that has spread to their bones and has failed to be controlled by hormone deprivation drugs.

18 Jul 2013

Cancer patients who receive chest radiation should screen for heart disease every 5-10 years

Cancer patients who receive chest radiation should be screened for heart disease every 5-10 years, according to the European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology (ESC) and the American Society of Echocardiography (ASE).

17 Jul 2013

Cancer patients who receive chest radiation should be screened for heart disease every 5-10 years

16 Jul 2013

Soligenix announces personalized medicine collaboration with SciClone

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942.

8 Jul 2013

CEA-Leti receives €1M from bpifrance to accelerate the development of liver-cancer detection system

CEA-Leti announced today €1 million in funding from bpifrance to accelerate preclinical development of a liver-cancer detection system called LipImage 815™.

4 Jul 2013

Rural women with breast cancer less likely to receive radiation therapy after lumpectomy

Rural women with breast cancer are less likely than their urban counterparts to receive recommended radiation therapy after having a lumpectomy, a breast-sparing surgery that removes only tumors and surrounding tissue, a study by Mayo Clinic and others found.

28 Jun 2013

Pretreatment PET staging of LS-SCLC associated with improved survival

Each year, 13 percent of all newly diagnosed lung cancer patients are diagnosed with small-cell lung cancer (SCLC). Approximately 39 percent of patients with SCLC are diagnosed with limited-stage disease, meaning the cancer is only present in one lung, but may have spread to lymph nodes or tissue between the lungs.

26 Jun 2013

Tulsa Cancer Institute: The first U.S. center to treat patient with Accuray's TomoHDA System

Accuray Incorporated, announced today that the Tulsa Cancer Institute is the first U.S. center to treat a patient with Accuray's TomoHDA System, the latest and most advanced innovation in the TomoTherapy product lineage designed to treat the full spectrum of cancer patients.

25 Jun 2013

Rural women with breast cancer less likely to receive radiation therapy after lumpectomy

25 Jun 2013

Researchers develop method to identify aggressive prostate cancers

Researchers at Moffitt Cancer Center and colleagues at Louisiana State University have developed a method for identifying aggressive prostate cancers that require immediate therapy. It relies on understanding the genetic interaction between single nucleotide polymorphisms. The goal is to better predict a prostate cancer's aggressiveness to avoid unnecessary radical treatment.

20 Jun 2013

Men with low-risk prostate cancers can choose watchful waiting for better quality of life, study says

Many men with low-risk, localized prostate cancers can safely choose active surveillance or "watchful waiting" instead of undergoing immediate treatment and have better quality of life while reducing health care costs, according to a study by researchers at Dana-Farber Cancer Institute and Massachusetts General Hospital.

18 Jun 2013

KLAS announces 2013 Best in KLAS Awards for medical equipment and infrastructure

KLAS just released the 2013 Best in KLAS Awards: Medical Equipment & Infrastructure report ranking the best-performing imaging, pharmacy automation and infrastructure vendors in the world.

From Elekta 15 Jun 2013

Black women with breast cancer experience treatment delays, new study finds

Black women with breast cancer are more likely than Hispanic or white women to experience delays in the initiation of chemotherapy or radiation after surgery, finds a new study in Health Services Research.

13 Jun 2013

Radionuclide drug treatment planning goes to next level with 3-D patient models

External beam radiation treatment has long been manipulated into the unique shape of patients' tumors for personalized cancer care. Technology providing a means of patient-specific radionuclide drug therapies has not been standardized, as it has been limited to software that requires oncologists to manually define the areas of tumors.

13 Jun 2013

International clinical study shows that BioProtect Balloon Implant has potential to reduce rectal injury

Several years ago, Virginia Commonwealth University Massey Cancer Center became the first center in the United States to test an Israeli-invented device designed to increase the space between the prostate and the rectum in prostate cancer patients undergoing radiation therapy.

11 Jun 2013

Radiation Therapy News and Research

Further Reading

New version of RaySearch's RayStation treatment planning system released for clinical use

Elekta gets CE Mark approval for Clarity 4D Monitoring system

Researchers patent biomaterial that generates artificial bones from umbilical cord stem cells

Phase 2 EORTC trial shows moderate dose radiotherapy is effective in desmoid-type fibromatosis patients

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

Study brings new hope for patients with metastatic prostate cancer

Cancer patients who receive chest radiation should screen for heart disease every 5-10 years

Cancer patients who receive chest radiation should be screened for heart disease every 5-10 years

Soligenix announces personalized medicine collaboration with SciClone

CEA-Leti receives €1M from bpifrance to accelerate the development of liver-cancer detection system

Rural women with breast cancer less likely to receive radiation therapy after lumpectomy

Pretreatment PET staging of LS-SCLC associated with improved survival

Tulsa Cancer Institute: The first U.S. center to treat patient with Accuray's TomoHDA System

Rural women with breast cancer less likely to receive radiation therapy after lumpectomy

Researchers develop method to identify aggressive prostate cancers

Men with low-risk prostate cancers can choose watchful waiting for better quality of life, study says

KLAS announces 2013 Best in KLAS Awards for medical equipment and infrastructure

Black women with breast cancer experience treatment delays, new study finds

Radionuclide drug treatment planning goes to next level with 3-D patient models

International clinical study shows that BioProtect Balloon Implant has potential to reduce rectal injury

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News